文献速递MDS 与骨髓增殖性肿瘤造血干细胞移植与细胞治疗

人源基因工程钙网蛋白突变干细胞重现骨髓增殖性肿瘤特征并揭示可靶向的脆弱性

Human gene-engineered calreticulin mutant stem cells recapitulate MPN hallmarks and identify targetable vulnerabilities.
PubMed 文献 · Leukemia · 2023-02-22

研究利用CRISPR/Cas9和腺相关病毒载体介导的敲入策略,在原代人造血干/祖细胞中构建首个CALR突变骨髓增殖性肿瘤人源化模型,该模型在体外和异种移植小鼠中重现了血小板生成素非依赖性巨核细胞生成、髓系偏移、脾肿大、骨髓纤维化及CD41+祖细胞扩增等特征,并发现CALR突变细胞对BiP伴侣蛋白和蛋白酶体抑制具有优先敏感性。

要点

  • 人源化CALR突变模型重现MPN关键特征:血小板生成素非依赖性巨核细胞生成、髓系偏移、脾肿大、骨髓纤维化及CD41+祖细胞扩增。
  • CALR突变强制人造血干/祖细胞早期重编程并诱导内质网应激反应,伴侣蛋白代偿性上调揭示突变特异性脆弱性。
  • CALR突变细胞对BiP伴侣蛋白抑制和蛋白酶体抑制具有优先敏感性。

核心结论

  • 人源化CALR突变模型优于纯小鼠模型,为在人源背景下测试新型治疗策略提供了可直接使用的基础。

研究设计与样本

  • 研究采用CRISPR/Cas9和腺相关病毒载体介导的敲入策略,在原代人造血干/祖细胞中构建CALR突变骨髓增殖性肿瘤人源化模型,并在体外和异种移植小鼠中验证。

主要发现

  • 人源化模型重现血小板生成素非依赖性巨核细胞生成、髓系 lineage 偏移、脾肿大、骨髓纤维化及巨核细胞primed CD41+祖细胞扩增。
  • CALR突变引入强制人造血干/祖细胞早期重编程并诱导内质网应激反应。
  • 伴侣蛋白代偿性上调揭示突变特异性脆弱性,CALR突变细胞对BiP伴侣蛋白抑制和蛋白酶体抑制具有优先敏感性。

关键数值与推荐

  • CALR突变细胞对BiP伴侣蛋白抑制和蛋白酶体抑制的敏感性高于对照。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Calreticulin (CALR) mutations present the main oncogenic drivers in JAK2 wildtype (WT) myeloproliferative neoplasms (MPN), including essential thrombocythemia and myelofibrosis, where mutant (MUT) CALR is increasingly recognized as a suitable mutation-specific drug target. However, our current understanding of its mechanism-of-action is derived from mouse models or immortalized cell lines, where cross-species differences, ectopic over-expression and lack of disease penetrance are hampering translational research. Here, we describe the first human gene-engineered model of CALR MUT MPN using a CRISPR/Cas9 and adeno-associated viral vector-mediated knock-in strategy in primary human hematopoietic stem and progenitor cells (HSPCs) to establish a reproducible and trackable phenotype in vitro and in xenografted mice. Our humanized model recapitulates many disease hallmarks: thrombopoietin-independent megakaryopoiesis, myeloid-lineage skewing, splenomegaly, bone marrow fibrosis, and expansion of megakaryocyte-primed CD41+ progenitors. Strikingly, introduction of CALR mutations enforced early reprogramming of human HSPCs and the induction of an endoplasmic reticulum stress response. The observed compensatory upregulation of chaperones revealed novel mutation-specific vulnerabilities with preferential sensitivity of CALR mutant cells to inhibition of the BiP chaperone and the proteasome. Overall, our humanized model improves purely murine models and provides a readily usable basis for testing of novel therapeutic strategies in a human setting.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Foßelteder J, Pabst G, Sconocchia T, et al. Human gene-engineered calreticulin mutant stem cells recapitulate MPN hallmarks and identify targetable vulnerabilities. Leukemia. 2023. PMID: 36813992. doi:10.1038/s41375-023-01848-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。